As research in tumor-targeted siRNA delivery steadily advances, we examine the functional ability of anti-FoxM1 siRNA to induce suppression of FOXM1 in tumors, as a proof-of-principle for the potential of anti-FoxM1 siRNA as a therapeutic agent. The gene discussed is FOXM1; the disease is neoplasm.